Related to this topic: Leaflets | Patient+ | UK Guidelines | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Septicaemia

Synonyms: Sepsis, blood poisoning

Septicaemia may not be obvious and a high index of suspicion is required to make the diagnosis, which is potentially fatal.

Definitions
  • Bacteraemia - presence of bacteria in the blood e.g. following dental procedures. Usually only a few numbers of bacteria and does not result in any problems. However, if the patient has damaged heart valves they are at risk of infective endocarditis.
  • Septicaemia - there are presence of numerous bacteria in the blood which are actively dividing. This results in a systemic response leading to organ dysfunction.

Septicaemia is a serious illness and often fatal. It can be complicated by circulatory collapse, myocardial depression, increased metabolic rate and vasoregulatory perfusion abnormalities. Thus it must not be viewed as simply being an infection alone.

The Surviving Sepsis Campaign was established in the last decade to raise awareness of severe sepsis and to improve its management.1 The Surviving Sepsis Campaign is a collaboration between several groups world wide and its aim is to reduce the mortality from sepsis. The Surviving Sepsis Campaign defines sepsis as a disease continuum with 3 groups:

SIRS, Sepsis and Severe sepsis1
SIRS (Systemic Inflammatory Response Syndrome) For adults: a clinical response arising from a nonspecific insult, including ≥2 of the following: Temperature (>30°C or <36°C), heart rate (>90 bpm), respiration rate (>20 per min or raised PCO2) or WCC (>12,000/mm3 or <4000/mm3).
Sepsis SIRS with presumed or confirmed infectious process.
Severe sepsis Sepsis with ≥1 sign of organ dysfunction, hypoperfusion or hypotension. Examples include septic shock or respiratory failure.
Pathophysiology of sepsis2

Sepsis involves a number of derangements, the following are a few:

  • Abnormal coagulation
  • Endothelial injury
  • Presence of excessive tumour necrosis factor
  • Cell apoptosis e.g. lymphocytes and endothelial cells
  • Neutrophil hyperactivity
  • Poor glycaemic control
  • Lack of steroid hormones
Epidemiology

The Surviving Sepsis Campaign estimates that the incidence of sepsis is 3 per 1000 worldwide. Thus the number of cases each year probably reaches 18 million and this associated with its high mortality rate, makes it a leading cause of death.3

Risk factors

There is usually an abscess or nidus of infection, which may be occult. Risk factors for developing sepsis include the following:

Presentation
  • Patients may present a few days earlier with a focus of infection
  • Patients may then deteriorate rapidly despite having the appropriate oral antibiotics
  • Non-specific symptoms are common e.g. lethargy, nausea and vomiting, abdominal pain and diarrhoea
  • Also inquire about symptoms relating to a possible focus of infection e.g. cough, recent travel
Clinical features
  • Looks unwell
  • Fever (maybe spiking) and/or rigors
  • Tachycardia, tachypnoea and cyanosis
  • Hyperdynamic circulation with a bounding pulse (early on)
  • Poor capillary refill and cold peripheries occur later
  • Hypotension with a postural drop (indicates septic shock)
  • Sweating
  • Lymphadenopathy
  • Hepatosplenomegaly
  • Drowsiness or impaired consciousness (common in the elderly but a late sign in young children and young adults)
  • Features relating to actual infection e.g. rash in meningococcal sepsis, dullness to percussion in pneumonia

These features may not be present in the very young, elderly and immunocompromised.

Investigations

Remember - septicaemia is a clinical diagnosis.

Investigations should include:

  • FBC - anaemia, neutrophilia or neutropenia, thrombocytopenia may be present (pancytopenia may indicate bone marrow involvement). In viral infections lymphocytosis predominates.
  • Urine dipstick and sample for microscopy, culture and sensitivity.
  • Renal function - looking at extent of dehydration or organ failure.
  • Liver function tests - hypoalbuminaemia likely to be present.
  • Glucose - hyperglycaemia can be present.
  • Clotting screen including d-dimers and fibrinogen looking for Disseminated Intravascular Coagulation (DIC).
  • Blood cultures - several sets from several sites are required. Cultures for mycobacteria should also be sent. Ideally these should be sent before antibiotics are given - but do not delay especially if patient very ill.
  • Radiology - including CXR, abdominal ultrasound looking for a collection, CT scan looking for source.
  • Measures of lactate and oxygen saturation of venous blood (SvO2 - see below).
  • Arterial blood gases - metabolic acidosis is common.
  • More invasive investigations looking for a source of infection - e.g. lumbar puncture, bronchoscopy, laparoscopy, lymph node biopsy etc.
Complications
  • Disseminated intravascular coagulation
  • Adrenal failure e.g. adrenal haemorrhage secondary to meningococcus (Waterhouse-Friedrichsen syndrome)
  • Multiorgan failure e.g. renal failure or cardio-respiratory failure
Management

Supportive care

  • Resuscitation - patients may require intubation and ventilation
  • Intravenous rehydration - aggressively if patient shocked
  • Intravenous hydrocortisone - patients may have adrenal dysfunction (consider especially if they have refractory hypotension)
  • Monitoring patient - this may require measures of central venous pressure and urinary output with a catheter
  • Intravenous insulin may be required until the septicaemia resolves

Specific therapy

  • Intravenous antibiotics - the choice should include broad spectrum antibiotics given intravenously. Once an organism is isolated then this regimen can be tailored for the patient.
  • Immunocompromised patients may have unusual organisms including fungi - thus help of microbiologist and virologist may be required.
  • Surgery may also be required e.g. wound debridement, abscess drainage.
Surviving Sepsis Campaign, early goal-directed therapy and "bundles"
  • The Surviving Sepsis Campaign was established to raise awareness of severe sepsis and to improve its management. It is a collaboration between the Society of Critical Care Medicine, the European Society of Intensive Care Medicine and the International Sepsis Forum.
  • The goal is to achieve a 25% global reduction in mortality from sepsis by the year 2009.
  • The campaign have devised guidelines which are divided into "bundles". Bundles represent groups of evidence-based recommendations within a single protocol. The idea is that following these bundles improves patient survival.
  • The guidelines highlight that early aggressive management of sepsis i.e. before the patient ends up in an intensive care setting is crucial for improving patient outcomes.4

Some of the recommendations include the following3

  • Aggressive rehydration titrated to a central venous pressure (CVP) of 8-12 mmHg - using high volumes of crystalloids
  • Earlier use of blood transfusion e.g. haemoglobin level <10g/dl provided patient resuscitated to CVP 8-12 mmHg
  • Using SvO2 to determine oxygenation of tissues. SvO2 is an estimate of oxygen saturation of blood returning to the right side of the heart. SvO2 <65% is associated with a worse prognosis and provided CVP, haemoglobin and mean arterial pressure are satisfactory, patients should be started on an dobutamine
  • Early and appropriate empirical antibiotic therapy

The Surviving Sepsis Campaign divides therapy into two bundles5

  1. Resuscitation bundle - complete within 6 hours of hospital attendance. This includes measuring serum lactate, obtaining blood cultures, broad-spectrum antibiotics, fluid resuscitation (for hypotension or high lactate levels) - using CVP and SvO2 as guidance, vasopressor therapy when adequate fluid resuscitation fails.
  2. Management bundle - complete within first 24 hours. This includes low-dose corticosteroids, glucose control, ventilatory support and the use of drotrecogin alfa (see below).


Initially when these guidelines were published there were concerns that the evidence on which they were founded was limited and some suspected there was too much involvement of the pharmaceutical industry.6 However, despite these concerns outcomes of the sepsis programmes are very good and on average a 20% reduction in overall mortality has been reported. In addition to this length of hospital stay is reduced resulting in this method to be cost-effective.3

Drotrecogin alfa (activated) for severe sepsis7

Drotrecogin alfa (activated) is a recombinant form of human activated protein C. Activated protein C (APC) enhances fibrinolysis, prevents thrombosis and has anti-inflammatory properties. In sepsis APC levels are reduced and there is also an inability to produce APC. It is given as an intravenous infusion and its main adverse effect is bleeding. Thus is not for use in patients who are actively bleeding, who have severe hepatic disease or intracranial pathology. See Summary of Product for full details.8 The PROWESS trial (Recombinant human protein C Worldwide Evaluation in Severe Sepsis), a phase III study was cut short as it was discovered that significant reductions in mortality were occurring in patients with severe sepsis receiving drotrecogin alfa.9

Thus NICE recommend its use for adult patients who have severe sepsis that has resulted in multiple organ failure (that is, two or more major organs have failed) and who are being provided with optimum intensive care support.

Prognosis

Sepsis, especially when there is a delay in institution of therapy is associated with 40% mortality (which increases to over 60% in the presence of septic shock).3 These figures can be improved with early goal directed therapy.


Document references
  1. Schlichting D, McCollam JS; Recognizing and managing severe sepsis: a common and deadly threat. South Med J. 2007 Jun;100(6):594-600. [abstract]
  2. Remick DG; Pathophysiology of sepsis. Am J Pathol. 2007 May;170(5):1435-44. [abstract]
  3. Otero RM, Nguyen HB, Huang DT, et al; Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings. Chest. 2006 Nov;130(5):1579-95. [abstract]
  4. Rivers E, Nguyen B, Havstad S, et al; Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77. [abstract]
  5. Patel GP, Elpern EH, Balk RA; A campaign worth joining: improving outcome in severe sepsis and septic shock using the Surviving Sepsis Campaign guidelines. South Med J. 2007 Jun;100(6):557-8.
  6. Eichacker PQ, Natanson C, Danner RL; Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006 Oct 19;355(16):1640-2.
  7. Sepsis (severe) - drotrecogin, NICE (2004)
  8. Specific Product Characteristics (SPC) Xigris® powder for solution for infusion, (Drotrecogin Alfa), Eli Lilly and Company Ld, July 2007.
  9. Bernard GR, Vincent JL, Laterre PF, et al; Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709. [abstract]

Internet and further reading Acknowledgements EMIS is grateful to Dr Gurvinder Rull for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 2765
Document Version: 20
DocRef: bgp320
Last Updated: 13 Mar 2008
Review Date: 13 Mar 2010






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site














Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page